Access Pharmaceuticals announced it has received approval to sell its mucositis treatment, MuGard, in China.
The company's partner in China, Rhei Pharmaceuticals, received regulatory and marketing approval from Chinese health officials to treat oral mucositis in cancer patients with MuGard, according to Access Pharmaceuticals. Access will start making the product shortly to meet the demand created by Jian An, Rhei's sales and marketing partner in China.
MuGard is a ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments, characterized by inflammation and erythema or ulcerations throughout the oral mucosa.
Last year, Access and Rhei signed a $30 million supply agreement for MuGard in the licensed territories. In addition, Access approved a sublicense agreement between Rhei and Jian An Pharmaceuticals to leverage Jian An's sales, marketing, and regulatory infrastructure for the launch of MuGard in China and Taiwan.
Jian An is headquartered in Shenzhen, China, and has a history of selling pharmaceutical and other medical products in the China market.
